

Target	Internalizing Aptamer	siRNA target	Type of conjugate	Tumor models (cells)	Reference
PSMA	A10	PLK1 – BCL2	“Two-blocks”	Prostate (LNCaP – 22Rv1)	[68]
PSMA	A10-3.2	PLK1	“Two-blocks”	Prostate (LNCaP – 22Rv1)	[69]
BAFF-R	R-1	STAT-3	“Two and Three blocks”	Lymphomas (Jeko-1 and Z138)	[70]
EpCAM	Anti-EpCAM aptamer	Survivin	“Two-blocks”	Breast (MCF-7/Adr)	[72]
EpCAM	Anti-EpCAM aptamer	PLK1	“Two-blocks”	Breast (MDA-MB-468)	[74]
PDGFR $\beta$	Gint4.T	STAT-3	“Three-blocks”	Glioma (U87MG – T98G)	[75]
PDGFR $\beta$	Gint4.T	STAT-3	“Three-blocks”	Patient-derived GSC	[76]
PDGFR $\beta$	Gint4.T	STAT-3	“Three-blocks”	NSCLC (Calu-1)	[77]
PSMA	A10-3.2	Survivin and EGFR	Bivalent aptamer-based “three-blocks conjugate	Prostate (C4-2)	[79]
HER2	Anti-HER2 aptamer	EGFR	Bivalent aptamer-based “three-blocks conjugate	Breast (BT474)	[80]
HER2 & HER3	Anti-HER2 & Anti-HER3	EGFR	Bivalent aptamer-based “three-blocks conjugate	Breast (BT474)	[81]

**Supplementary Table 2: Aptamer-based siRNA conjugates.** A summary of the aptamer-siRNA conjugates which are discussed in the review. The table includes information regarding the aptamer used, its recognized target, the siRNA conjugated to the aptamer, the type of conjugation according to the classification discussed, and the cellular models used for the validation.